Eagle Pharmaceuticals, Inc.
EGRX · OTC
3/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | – | $55 | $98 | $103 |
| Short-Term Investments | – | $0 | $0 | $0 |
| Receivables | – | $73 | $41 | $51 |
| Inventory | – | $48 | $22 | $8 |
| Other Curr. Assets | – | $12 | $12 | $4 |
| Total Curr. Assets | – | $189 | $173 | $166 |
| Property Plant & Equip (Net) | – | $1 | $2 | $2 |
| Goodwill | – | $45 | $40 | $40 |
| Intangibles | – | $118 | $11 | $13 |
| Long-Term Investments | – | $10 | $0 | $12 |
| Tax Assets | – | $27 | $19 | $15 |
| Other NC Assets | – | $16 | $10 | $5 |
| Total NC Assets | – | $217 | $81 | $87 |
| Other Assets | – | $0 | $0 | $0 |
| Total Assets | – | $406 | $254 | $253 |
| Liabilities | – | – | – | – |
| Payables | – | $19 | $16 | $6 |
| Short-Term Debt | – | $8 | $27 | $9 |
| Tax Payable | – | $5 | $0 | $0 |
| Deferred Revenue | – | $0 | $25 | $0 |
| Other Curr. Liab. | – | $79 | $6 | $23 |
| Total Curr. Liab. | – | $111 | $74 | $38 |
| LT Debt | – | $60 | $3 | $29 |
| Deferred Rev, NC | – | $0 | -$2 | -$6 |
| Deferred Tax Liab, NC | – | $0 | $2 | $2 |
| Other NC Liab. | – | $4 | -$0 | $4 |
| Total NC Liab. | – | $62 | $3 | $29 |
| Other Liabilities | – | $0 | $0 | $0 |
| Cap. Leases | – | $5 | $4 | $5 |
| Total Liabilities | – | $173 | $77 | $67 |
| Equity | – | – | – | – |
| Pref Stock | – | $0 | $0 | $0 |
| Common Stock | – | $0 | $0 | $0 |
| Retained Earnings | – | $112 | $76 | $84 |
| AOCI | – | -$1 | -$0 | $0 |
| Other Equity | – | $123 | $101 | $102 |
| Total Equity | – | $234 | $176 | $186 |
| Supplemental Information | – | – | – | – |
| Minority Interest | – | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | – | $406 | $254 | $253 |
| Net Debt | $0 | $12 | -$68 | -$65 |